Global Pharmaceutical Analytical Testing Services Market: Snapshot 

The global pharmaceutical analytical testing services market is poised to soar owing to the rising demand from pharmaceutical manufacturers and raw material suppliers. Delivering comprehensive pharmaceutical services in manufacturing and development have become the key concern of several companies. Numerous service providers are offering services such as pharma solutions, packaging, residual solvents, stability testing and storage, method validation, dissolution, raw material testing, leachable or extractable testing, and retrospective method validation.

Get an idea about the offerings of our Report from REPORT BROCHURE HERE

A major trend observed in the global pharmaceutical analytical testing services market is outsourcing. Absence of the necessary set-up for performing every test in-house is one of the key reasons for outsourcing. The best method for handling tests such as process and facility validation, registration stability storage and testing, analytical testing that deploys expensive equipment, cleaning validations, and method development is outsourcing. Outsourcing to a specialty company provides experience and expertise in this domain. It also aids in bringing down the costs of maintenance, equipment, and validation. As a result, outsourcing is likely to contribute towards the expansion of the global pharmaceutical analytical testing market.

The clinical bioanalytical testing segment is slated to grow at a considerable pace during the forecast period, attaining a significant share of the global market for pharmaceutical analytical testing services. The factors responsible for the growth of this region are stringent regulatory framework applicable to drug discovery and the rising number of clinical trials driven by the increasing incidence of diseases.

With the advent of several technological advancements, numerous new solutions are being developed. For example, in March 2017, a cost efficient system that enables pharmaceutical label-free ultra-high throughput screening has been launched by Bruker. The pharmaceutical industry has been increasingly deploying NMR fragment-based screening method, which has been incorporated into Bruker’s new software. Increased efficiency, productivity and reliability are some key features of this screening method.

Pharmaceutical Analytical Testing Services Market: Comprehensive Overview

Pharmaceutical analytical testing services are services offered to several pharmaceutical manufacturers, product manufacturers, and raw material suppliers. The need for increased efficiency and cost reduction by pharmaceutical companies has led to the rising scope for outsourcing analytical testing services. Currently there are a number of companies focusing on providing comprehensive pharmaceutical manufacturing and development services such as manufacturing and packaging, pharmaceutical development, analytical testing services, and pharma solutions. Service providers are also offering several pharmaceutical analytical testing services, such as method development/ method validation, stability testing and storage, raw material testing, residual solvents, dissolution, retrospective method validation, and extractable/leachable testing.

The market for pharmaceutical analytical testing services has been analyzed by taking into consideration the revenue generated by various analytical testing services such as raw material testing, stability testing, and method validation and testing. The report gauges various trends in analytical services across four major geographies: North America, Asia Pacific, Europe, and the Rest of the World (RoW).

Pharmaceutical Analytical Testing Services Market: Drivers and Restraints

The global market for pharmaceutical analytical testing services is driven by the growing need for the development and cost reduction of core competencies by pharmaceutical companies and the rising acceptance of outsourcing as a key business and growth strategy. Research studies have exhibited that in the year 2012, pharmaceutical and biotechnological companies spend an estimated US$190 mn on in-house analytical development as against the US$664 mn spent on outsourcing analytical testing services. This is likely to strengthen the growth of the market in the coming years.

On the other hand, the lack of skilled professionals and well-established healthcare infrastructure are some of the factors that threaten to hamper the growth of the pharmaceutical analytical testing services market. Apart from this, operational costs, fluctuations in good manufacturing practices (GMP), regulatory policies, and less turnaround times also impact the market growth.

Pharmaceutical Analytical Testing Services Market: Regional Outlook 

North America is one of the leading regions in the pharmaceutical analytical testing services market and is driven by familiarity with the regulatory scenario and the presence of well-established outsourcing infrastructure. The growth landscape of the Europe pharmaceutical analytical testing services market is slowly catching up, experts have observed.

Countries in Asia Pacific present significant growth potential thanks to the presence of a large pool of skilled professionals and relatively low operational costs. Rising investments in research is also a major factor driving the APAC pharmaceutical analytical testing services market. Investments in routine testing, multiplex protein profiling, biologics such as RNA sequencing, and others are likely to give Asia Pacific the boost it needs over the course of the forecast period.

Pharmaceutical Analytical Testing Services Market: Key Players

Some of the leading pharmaceutical analytical testing service providers are Pace Analytical Services, Inc., Intertek Group plc, Aptuit, Inc., and West Pharmaceutical Services, Inc. The vendor landscape of the pharmaceutical analytical testing services market has evolved over the recent past owing to rising mergers, strategic parternships, and downsizing in the pharma sector. In addition to this, increased focus on strengthening internal core competencies and the rising need and demand for faster analytical response fuel the market for pharmaceutical analytical testing services.

Request TOC of the Report for more Industry Insights @ CLICK HERE NOW

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Global Personalized Cancer Drugs Market: Snapshot

Genetic sequencing has proven that no two cancer cases are absolutely identical, heavily depending on genetic profiles of the patients, which defines their immunity power. But frequently, several promising pipeline drugs fail to reach the market for not being commonly useful for the masses. In this scenario, a small but increasing number of personalized cancer drugs are allowed by the FDA for the treatment of particular mutations. Nearly one third of cancer drugs are prescribed off-label, as it provides help to the patients immediately. These targeted agents are directed at specific molecular feature of the cancer cells and hence produce greater effectiveness with significantly less toxicity.

Get an idea about the offerings of our Report from REPORT BROCHURE HERE

The global market for personalized cancer drugs market is gaining traction from increased government support for precision-medicine. For example, in June 2016, the U.S. National Cancer Institutes revealed its plans to enroll thousand patients in a trial called NCI-MATCH, which is aimed at matching patients to twenty possible compounds on the basis of their genetic abnormalities. Along the similar lines, The American Society of Clinical Oncology has also announced a registry termed as TAPUR, collecting data on the fate of patients who receive personalized cancer drugs off-label.

Another factor driving the global personalized cancer drugs market is the falling cost of genetic sequencing, which is enabling the quick approval of drugs for off-label clinical trials on patients in need across the world.

Personalized Cancer Drugs Market: Overview

Personalized drugs, or customized drugs, are tailored to suit the needs of individual patients. Earlier, various patients suffering from the same type of disease were given the similar treatment plan. However, it became evident to physicians that a particular treatment worked differently for different patients, mainly owing to a varied genetic makeup. The concept of personalized medicine is based on the analysis of etiology of disease in individual patients and offers treatment that is more efficient, predictable, and precise.

Cancer is a common chronic disease and a major cause of fatality around the globe. The development of personalized cancer drugs has gained pace as they have relatively fewer side effects compared to standard drugs. Personalized cancer drugs target a specific protein or gene responsible for the growth and survival of a cancer type.

Personalized Cancer Drugs Market: Trends and Opportunities

The personalized cancer drugs market is primarily fueled by the rising prevalence of various cancer types such as lung cancer, breast cancer, prostate cancer, melanoma and leukemia, and colorectal cancer. According to the Surveillance, Epidemiology, and End Results Program sponsored by the National Cancer Institute (NCI), an estimated 13,397,159 people in the United States were affected with various cancer types in 2011. Moreover, in 2014, around 1,666,540 new cancer cases were diagnosed in the country, with nearly 585,720 deaths resulting from cancer. The personalized cancer drugs market is also driven by several advantages associated with this new treatment therapy and ongoing developments in the field of genetic science.

On the flip side, high cost associated with the genetic testing of patients and tumor samples may serve as a growth restraint on the market for personalized cancer drugs. In addition to this, the lack of insurance plans to cover these tests in developing nations of Asia Pacific and Rest of the World hampers the market to some extent. This can be attributed to low per capita income and poor reimbursement scenario.

Personalized Cancer Drugs Market: Geographical Assessment

From a geographical perspective, the personalized cancer drugs market has been broadly segmented into Europe, Asia Pacific, North America, and Rest of the World (RoW). The market for personalized cancer drugs is led by North America. The chief factors responsible for the region’s lead position are aggressive research and development activities, technical advancements, higher affordability for expensive treatments and therapies, and greater healthcare awareness. Europe is also a key market for personalized cancer drugs owing to significant funding from several governments and the growing penetration by U.S.-based companies.

Asia Pacific holds immense promise for players in the personalized cancer drugs market, powered mainly by Japan. The regional market is likely to be fueled by the presence of a large pool of cancer patients and improving healthcare infrastructure. The growth of the APAC personalized cancer market can also be attributed to the rapidly evolving medical tourism industry. In the RoW segment, Mexico, Brazil, Russia, and South Africa represent potential markets.

Personalized Cancer Drugs Market: Competitive Landscape

Some of the key players competing in the personalized cancer drugs market are F. Hoffmann-La Roche Ltd., Pfizer Ltd., Cell Therapeutics, Inc., H3 Biomedicine, Inc., bioTheranostics, GlaxoSmithKline, and Abbott Laboratories. Zelboraf (vemurafenib) by F. Hoffmann-La Roche Ltd. and Xalkori (crizotinib) by Pfizer Ltd. are some notable targeted drugs for the treatment of cancer.

Request TOC of the Report for more Industry Insights @ CLICK HERE NOW

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Global Hysterometers Market: Overview 

The National Women’s Health Network (NWHN) states that the hysterectomy is the second most frequently performed surgical procedure in the U.S. The data published by the Centers for Disease Control and Prevention (CDC) states that from 2006 to 2010, 11.7% of women of the age group from 40 to 44 has a hysterectomy. The surgical procedure is performed in several cases to save women from life threating diseases or health conditions such as invasive cancer of the cervix, uterus, vagina, ovaries, and fallopian tubes. Additionally, it is most helpful in the treatment of unmanageable infection, unmanageable bleeding, and to avoid grave complications during childbirth. Rising incidences of these health conditions, the investment on the adopting hydrometers is growing continuously, which is benefiting the growth of the hysterometers market.

Get an idea about the offerings of our Report from REPORT BROCHURE HERE

Global Hysterometers Market: Notable Developments 

• The hysterometers market features a fragmented vendor landscape as a large number of players are operating globally. Additionally, a rise in demand in the hysterometers is leading to increasing the competitiveness of the market. Thus, in order to stand alone in the market and to grab a competitive edge, the players are increasingly investing in research and development.

• Moreover, the high adoption of the hysterometers across hospitals is estimated to continue in the coming years. The rise in the number of gynecology procedures held in the hospitals boosted demand for related medical devices such as hysterometers. These factors are estimated to benefit market growth in the coming years. 

Some of the most prominent competitors operating in the competitive landscape of global hysterometers market include –

• Novomed Group
• Ri.Mos. Srl
• Prince Medical SAS
• Surtex Instruments Ltd.
• The Cooper Co. Inc.
• TG Eakin Ltd.

Global Hysterometers Market: Drivers and Restraints 

The global hysterometers market is gaining traction on the back of the rising incidences of the invasive cancer of the cervix, uterus, vagina, ovaries, and fallopian tubes. Increase in the occurrence of these types of cancer has led to creating a grave need for effective measures. Thus, the adoption of hysterometers is increasing. Additionally, rising incidences of the infections to the vagina and urinary tract, and uterus due to fungus and other serious issues is boosting the need for advanced medications, which is augmenting the adoption of the hysterometers. These are key factors driving the growth of the hysterometers market.

Additionally, due to issues pertaining to abnormal bleeding in women can be easily handled with the help of the hysterometers. This is again a key factor in boosting the hysterometers market. However, slower FDA approvals for the newer treatments and devices are restraining growth of the global hysterometers market. Additionally, the possibility of side effects is restraining the growth of the global hysterometers market. Nonetheless, technological advancements in the hysterometers are estimated to propel market growth in the coming years. 

Global Hysterometers Market: Regional Outlook 

On the basis of region, the hysterometers market is segmented into North America, Europe, Latin America, Asia Pacific, and the Middle East & Africa. Of these, North America is expected to dominate the global hysterometers market and is likely to remain dominant in the coming years. This is attributable to the increased awareness level coupled with the presence of advanced technologies in the region. Europe is estimated to account for a second-leading share in the global revenue owing to the rising geriatric population in the region and advent of advanced technologies. However, the market in the Asia Pacific is estimated to witness growth with most lucrative CAGR in the coming years. This growth is attributable to the rising awareness about health and advent of newer technologies pertaining to hysterometers in the region.

Request TOC of the Report for more Industry Insights @ CLICK HERE NOW

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050